CellFE and Made Scientific Announce Strategic Collaboration to Advance Non-viral Gene Editing for T Cell Therapies
CellFE and Made Scientific announce a strategic collaboration to generate pilot data on the CellFE High Volume Cyva™ System.
News
Categories
20 Results for ""
CellFE Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular Therapies
CellFE, a leader in non-viral gene editing technology, announces a strategic collaboration with the Harbottle Lab at German Cancer Research Center (DKFZ) and its spin-out company, TcellTech.
Application Note: Efficient Gene Editing of iPSCs
CellFE releases a cGMP-compatible workflow to support highly efficient gene editing of iPSCs via a non-viral approach for cell therapy manufacturing.
CellFE Announces Launch of First-in-Class T-Rest (“Resting T Cell Kit”) for Breakthrough CAR-T Cell Therapy Manufacturing
CellFE® today announced the launch of its highly anticipated CellFE T-Rest™, a first-in-class cell manufacturing transfection media product designed specifically for resting T cell workflows, along with an app note.
Application Note: CellFE CAR T Cell Editing
In the rapidly evolving field of cellular engineering, achieving complex gene edits with high efficiency and minimal workflow disruption remains a significant challenge.
CellFE Announces Addition of Life Science Tools Veteran Mike Rice to Board of Directors
CellFE Appoints Mike Rice to Board of Directors
CellFE Announces Presentations at International Society of Gene & Cell Therapy (ISCT) 2024 Annual Meeting
CellFE announced today an upcoming presentation by CEO Alla Zamarayeva, PhD, at the International Society of Gene & Cell Therapy (ISCT) Annual Meeting, taking place May 29-June 1, 2024 in Vancouver, BC.
CellFE Announces May 2024 Conference Presentations
CellFE announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD.
CellFE secures $22 million in Series A financing to advance microfluidics-based cellular engineering platform
CellFE announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures, Riverine Ventures and its existing investors.
Endpoints News: CellFE raises $22M Series A to advance a new cell therapy manufacturing idea
Exclusive: The California-based startup CellFE has raised a $22 million Series A to advance a new approach to making cell therapies with microfluidics.
CellFE unveils research scale microfluidics-based cell engineering platform at BIO2022
The BIO International Convention (BIO) returns to in person meetings in San Diego, CA June 13-16 and CellFE will be there to present the…
CEO and Co-Founder Alla Zamarayeva presents in the Startup Showcase session at the ASGCT Annual
CEO and Co-Founder Alla Zamarayeva PhD presented recently at the Startup Showcase at the ASGCT 25th Annual Conference.